Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Tuscano

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
The Journal of Rheumatology|November 3, 2005
Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatmentJean Higashida, Ted Wun, Sara Schmidt, et al.
Ultrastructural Pathology|July 18, 2025
Light chain crystalline podocytopathy caused by electron-lucent crystals - a diagnostic challenge: a case reportRajib K Gupta, Maria E Pagtalunan, Ann M Wexler, et al.
Current Issues in Molecular Biology|September 27, 2023
A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In VivoDaniel J Levis, Joshua F Meckler, Robert T O'Donnell, et al.
Cancer Immunology, Immunotherapy : CII|May 29, 2023
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor modelJoshua F Meckler, Daniel J Levis, Daniel P Vang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse modelJoseph M Tuscano, Shiloh M Martin, Yunpeng Ma, et al.
Accounts of Chemical Research|June 18, 2003
Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction researchKit S Lam, Ruiwu Liu, Suzanne Miyamoto, et al.
Cancer Immunology, Immunotherapy : CII|May 14, 2009
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenograftsRobert T O'Donnell, Yunpeng Ma, Hayes C McKnight, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2011
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies aloneJoseph M Tuscano, Yunpeng Ma, Shiloh M Martin, et al.
Leukemia Research|February 25, 2009
Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cellsRobert T O'Donnell, David Pearson, Hayes C McKnight, et al.
Cancer Immunology, Immunotherapy : CII|March 19, 2009
Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacyRobert T O'Donnell, David Pearson, Hayes C McKnight, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Rheumatology|November 3, 2005
Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatmentJean Higashida, Ted Wun, Sara Schmidt, et al.
Ultrastructural Pathology|July 18, 2025
Light chain crystalline podocytopathy caused by electron-lucent crystals - a diagnostic challenge: a case reportRajib K Gupta, Maria E Pagtalunan, Ann M Wexler, et al.
Current Issues in Molecular Biology|September 27, 2023
A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In VivoDaniel J Levis, Joshua F Meckler, Robert T O'Donnell, et al.
Cancer Immunology, Immunotherapy : CII|May 29, 2023
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor modelJoshua F Meckler, Daniel J Levis, Daniel P Vang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse modelJoseph M Tuscano, Shiloh M Martin, Yunpeng Ma, et al.
Accounts of Chemical Research|June 18, 2003
Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction researchKit S Lam, Ruiwu Liu, Suzanne Miyamoto, et al.
Cancer Immunology, Immunotherapy : CII|May 14, 2009
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenograftsRobert T O'Donnell, Yunpeng Ma, Hayes C McKnight, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2011
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies aloneJoseph M Tuscano, Yunpeng Ma, Shiloh M Martin, et al.
Leukemia Research|February 25, 2009
Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cellsRobert T O'Donnell, David Pearson, Hayes C McKnight, et al.
Cancer Immunology, Immunotherapy : CII|March 19, 2009
Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacyRobert T O'Donnell, David Pearson, Hayes C McKnight, et al.
Pageof 7